MeiraGTx rises as Oberland Capital commits up to $400 mln for late-stage gene therapies

MeiraGTx Holdings

07/07/2026 12:40

** Shares of gene therapy firm MeiraGTx MGTX.O rise 7.3% to $14.90 premarket
** Co says it secured up to $400 mln from Oberland Capital to advance three late-stage experimental gene therapies
** Funding includes up to $375 mln in non-dilutive financing tied to future sales royalties and up to $25 mln in equity investment
** Co says it has already received $135 mln, including $125 mln for future royalties and $10 mln in equity
** Additional $150 mln available upon positive trial data and regulatory approvals expected in 2027-2028
** Oberland may provide another $100 mln for new products or business development and can buy an additional $15 mln in MeiraGTx shares, MGTX says 
** As of last close, stock was up ~75% YTD


 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))